Piramal Pharma
Piramal Pharma Limited is a global pharmaceutical company operating a CDMO (Piramal Pharma Solutions), an inhaled anesthetics and hospital generics business (Piramal Critical Care), and an India-focused OTC consumer healthcare division (Piramal Consumer Healthcare), serving pharma innovators, hospitals, and Indian consumers across 17 facilities in 100+ countries.
- Company typePublic
- Founded2020
- HeadquartersMumbai, India
- Headcount5,001–10,000
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What Piramal Pharma does
Piramal Pharma Limited is a publicly listed (BSE/NSE ticker PPL) global pharmaceutical company headquartered in Mumbai, India, operating across four segments: Piramal Pharma Solutions (PPS), a Contract Development and Manufacturing Organization (CDMO); Piramal Critical Care (PCC), a hospital generics and inhaled anesthetics franchise; Piramal Consumer Healthcare (PCH), an India-focused OTC business with brands such as Little's, Lacto Calamine, i-pill, Tetmosol, and Polycrol; and a joint venture with AbbVie in ophthalmic therapeutics.
The CDMO segment, which contributed approximately 55% of revenue, operates a network of 17 globally integrated development and manufacturing facilities across India, the United States, the United Kingdom, and Canada, offering end-to-end services from API synthesis and peptide manufacturing through formulation development and sterile fill-finish. Differentiated technical capabilities include the ADCelerate platform for accelerated antibody-drug conjugate (ADC) development, the Grangemouth UK facility — the first FDA-approved ADC CDMO globally with 1,500 batches delivered — specialized payload-linker manufacturing at Riverview, Michigan, Band 5 HPAPI containment, and proprietary digital platforms (eLab, exForms, iAssist) supported by an enterprise-wide Project Catalyst NxGen ERP transformation.
The company generates revenue through contract-based development fees and commercial supply agreements in CDMO, hospital-channel sales of generics and anesthetics in Critical Care, and Indian retail/e-commerce distribution in Consumer Healthcare. FY26 disclosed revenue was ₹8,869 crore, with management publicly targeting a doubling to approximately $2 billion by FY30. Key customers disclosed include Botanix SB Inc., NewAmsterdam Pharma, Plus Therapeutics, Bolt Biotherapeutics, Theracosbio, and Theratechnologies, alongside strategic co-development partnerships with Ajinomoto Bio-Pharma, IntoCell, and Blue-Zone Technologies.
Piramal Pharma firmographics
Firmographics- Name
- Piramal Pharma
- Legal name
- Piramal Pharma Limited
- Website
- https://piramalpharma.com
- Company type
- Public
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Piramal Pharma Limited is a global pharmaceutical company operating a CDMO (Piramal Pharma Solutions), an inhaled anesthetics and hospital generics business (Piramal Critical Care), and an India-focused OTC consumer healthcare division (Piramal Consumer Healthcare), serving pharma innovators, hospitals, and Indian consumers across 17 facilities in 100+ countries.
- Ownership category
- akta.pro rank
Piramal Pharma industry classification
Industry- Product category
- Pharmaceutical Manufacturing and CDMO Services
- NAICS
- Pharmaceutical and Medicine Manufacturing (32541), Drugs and Druggists' Sundries Merchant Wholesalers (42421)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)
- akta.pro secondary industry
- Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF) (HLAGAKAH)
Keywords
Where Piramal Pharma is headquartered
LocationHeadquarters
- HQ city
- Mumbai
- HQ country
- India
- HQ region
- Asia
Offices18 records
Markets served
Piramal Pharma business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Pharma Solutions (CDMO): Contract Development and Manufacturing Organization providing end-to-end drug development and manufacturing services to pharmaceutical innovators. Revenue generated through service contracts, development fees, and commercial manufacturing supply agreements. Represents the largest revenue segment at approximately 55% of total revenue.
- Critical Care: Hospital generics business focused on inhaled anesthetics and critical care medications. Products sold to hospitals and healthcare facilities globally through direct sales and distribution partnerships.
- Consumer Healthcare: India-focused consumer healthcare business with established OTC brands including Littles, Lacto Calamine, i-pill, Tetmosol, Polycrol, and Tri-Activ. Revenue from product sales through retail distribution channels.
- Complex Hospital Generics: Complex hospital generics including injectables and specialized pharmaceutical products. Growth segment including the Kenalog brand acquisition for hospital-based therapies.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Piramal Pharma product offering
Product offeringCore offering
Piramal Pharma is a global integrated pharmaceutical company providing end-to-end contract development and manufacturing (CDMO) services, critical care pharmaceuticals including inhalation anesthetics and injectables, and consumer healthcare OTC products. The company serves top 20 biopharma companies, global hospital networks, and retail consumers through 17 manufacturing facilities across India, the US, the UK, and Canada.
Product overview
Piramal Pharma Limited operates as a diversified global pharmaceutical company with four distinct business segments: Piramal Pharma Solutions (PPS) as a Contract Development and Manufacturing Organization offering end-to-end drug development and manufacturing services; Piramal Critical Care (PCC) specializing in inhaled anesthetics and hospital generics; Piramal Consumer Healthcare (PCH) with established OTC brands including Little's, Lacto Calamine, i-pill, Tetmosol, Polycrol, Tri-Activ, and i-choose; and AbbVie Therapeutics India for ophthalmic products. The company also operates the ADCelerate platform for rapid integrated ADC development. PPS maintains facilities across North America, Europe, and Asia, providing services from API synthesis through finished dosage manufacturing, with digital platforms including eLab, exForms, and iAssist supporting quality and compliance operations.
Differentiator
Problem solved
Functional benefit
Brands
- Piramal Pharma Solutions: Contract Development and Manufacturing Organization (CDMO) offering end-to-end development and manufacturing solutions across the drug lifecycle
- Piramal Critical Care
- Piramal Consumer Healthcare
- AbbVie Therapeutics India
Products and services
- Piramal Pharma Solutions (CDMO Services) End-to-end contract development and manufacturing organization (CDMO) services for global biopharma companies, covering drug substance and drug product development, manufacturing, and commercialization across small molecules, biologics, and antibody-drug conjugates. Customers include top 20 biopharma companies.
- Piramal Critical Care Critical care pharmaceutical products including inhalation anesthetics and injectable products sold to hospitals, healthcare institutions, and government health systems globally. The company is among the global leaders in inhalation anesthesia products.
- Piramal Consumer Healthcare Over-the-counter (OTC) consumer healthcare and personal care brands sold through retail pharmacy chains and modern trade in India, including established brands such as Lacto Calamine and Jungle Magic.
- AbbVie Therapeutics India (Joint Venture) Joint venture with AbbVie for the sale and distribution of AbbVie's pharmaceutical products in the Indian market, leveraging Piramal's established India sales and distribution infrastructure.
Quantifiable outcome
- Delivered over 70 regulatory approvals across global network in single fiscal year
- +4 more outcomes
Companies that use Piramal Pharma
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
Piramal Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability7 records
Feature7 records
Piramal Pharma partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core and minor.
- Botanix SB Inc.coreManufacturing and supply arrangement to develop and validate Sofpironium Bromide at Piramal's Riverview, Michigan facility with optional validation at its Aurora, Canada facility
- BrePco BiopharmaminorJoint development of Neoatricon for pediatric critical care, received MHRA approval for UK market
- Ajinomoto Bio-Pharma ServicescoreCollaboration to support ADC development and manufacturing, combining Piramal's payload-linker capabilities with Ajinomoto's biopharma expertise
- Blue-Zone Technologies Ltd.minorCollaboration for capture, collection and recycling of waste anesthesia gas. Subject to regulatory approval, Blue-Zone will supply Phoenix Deltasorb system to PCC customers in France and Germany, while PCC processes captured anesthetic gas to produce Sevofluran USP for human use in Canada
- IntoCellcorePartnership expanding Piramal's payload-linker platform and bioconjugate capabilities through IntoCell's specialized technologies
- NewAmsterdam PharmacoreInvestment in dedicated suite to enhance oral solid dosage production capabilities at Piramal's Sellersville, Pennsylvania site
- TheracosbiominorIntegrated drug substance/drug product program for Bexagliflozin
- Plus Therapeutics, Inc.minorMaster services agreement for investigational drug manufacturing for ongoing and planned clinical trials
- Theratechnologies Inc.minorSterile fill/finish program for TH1902 peptide-drug conjugate
- Epirium BiominorExclusive integrated development and manufacturing program for orphan drugs
- Bolt BiotherapeuticsminorIntegrated development program for immune-stimulating antibody conjugates and sterile fill-finish
- Medivant HealthcareminorStrategic partnership with US-based pharmaceutical outsourcing facility for critical care product distribution
- G&W Laboratories Inc.coreAcquisition of solid oral dosage drug product facility in Sellersville, Pennsylvania from G&W Laboratories Inc.
- BerGenBiominorCollaboration on development of FDA Fast Track designated leukemia treatment
Scale indicators14 records
Recent moves16 records
Expansion highlights6 records
Piramal Pharma competitors and assessment
Company assessmentMarket position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Piramal Pharma social profiles
Digital presencePiramal Pharma compliance and trust
Trust signalCompliance10 records
Piramal Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Piramal Pharma leadership team
Management profileNumber of profiles
Piramal Pharma subsidiaries and ownership
Company hierarchySubsidiaries8 records
Piramal Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Piramal Pharma M&A and investment
M&A and investmentM&A
Investments1 record
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Piramal Pharma
What does Piramal Pharma do?
Piramal Pharma is a global integrated pharmaceutical company providing end-to-end contract development and manufacturing (CDMO) services, critical care pharmaceuticals including inhalation anesthetics and injectables, and consumer healthcare OTC products. The company serves top 20 biopharma companies, global hospital networks, and retail consumers through 17 manufacturing facilities across India, the US, the UK, and Canada.
Is Piramal Pharma a public or private company?
Piramal Pharma is a public company. It is classified as public and is currently operating.
When was Piramal Pharma founded?
Piramal Pharma was founded in 2020. It employs 5,001 to 10,000 people.
Where is Piramal Pharma based?
Piramal Pharma is headquartered in Mumbai, India, in the Asia region.
How does Piramal Pharma make money?
Four revenue lines are on record. Pharma Solutions (CDMO) is the primary driver. The others are critical Care, consumer Healthcare and complex Hospital Generics.
Does Piramal Pharma have an API?
No public API is recorded for Piramal Pharma.
What industry is Piramal Pharma in?
Piramal Pharma's product category is Pharmaceutical Manufacturing and CDMO Services. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAGAKAH, Pharmacovigilance Quality & Compliance (PV audits, QPPV support, PSMF). Its NAICS code is 32541 and its SIC code is 2834.